About Biofrontera
Biofrontera is a company based in Leverkusen (Germany) founded in 1997. The company has 93 employees. Biofrontera has completed 1 acquisition, including Cutanea Life Sciences. Biofrontera offers products and services including Photodynamic Therapy Products and Topical Antibiotics. Biofrontera operates in a competitive market with competitors including Revance Therapeutics, Dermavant, Sol-Gel Technologies, SkinMedica and Hugel, among others.
- Headquarter Leverkusen, Germany
- Employees 93
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website biofrontera.com
- Social LinkedIn
- Legal Name Biofrontera Inc.
- Annual Revenue$15.5 M (USD)8.26as on Dec 31, 2025
- Net Profit-$4.65 M (USD)8.85as on Dec 31, 2025
- EBITDA-$748.48 K (USD)41.99as on Dec 31, 2025
- Latest Funding Round$11M (USD), Post-IPO
Jun 2025
- InvestorsNRW
& 1 more
- Employee Count93
- Investments & Acquisitions
Products & Services of Biofrontera
Biofrontera offers a comprehensive portfolio of products and services, including Photodynamic Therapy Products and Topical Antibiotics.
Treatments for pre-cancerous skin lesions using light-based therapy.
Medications for bacterial infections like impetigo.
Funding Insights of Biofrontera
- Total Rounds 11
- Last Round Post-IPO — $11M
- First Round $5.13M
(Feb 2004)
- Investors Count 2
Latest 10 of 11 funding rounds of Biofrontera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $11M | Post-IPO | – | – | – |
| Feb 2024 | $16M | Post-IPO | – | – | |
| Nov 2021 | $15M | Post-IPO | – | – | – |
| Jul 2020 | $9.37M | Post-IPO | – | – | – |
| May 2017 | $21.78M | Debt – Conventional | – | – | – |
| Apr 2016 | $5.53M | Post-IPO | – | – | – |
| Feb 2016 | $4.93M | Post-IPO | – | – | – |
| Nov 2015 | $3.73M | Post-IPO | – | – | – |
| May 2015 | $3.37M | Post-IPO | – | – | – |
| Nov 2006 | $8.52M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Biofrontera
Biofrontera has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NRW and Rosalind Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides investment management for life sciences and biotech funds to investors worldwide. | 2006 | rosalindcap.com | Toronto, Canada | |
Government programs access and development services are provided by NRW. | 1946 | land.nrw | Dusseldorf, Germany |
Investor details for Biofrontera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biofrontera
23 people are tracked at Biofrontera (7 in leadership, 5 in board & advisors, 11 in team); the tracked headcount is 93.
| Name | Role | Group |
|---|---|---|
Hermann Lübbert | CEO | Leadership |
Thomas Schaffer | CFO | Leadership |
Steffen Dammers | Head Of Quality Control | Leadership |
Frieda Schindler | Head Of Pharma Operations | Leadership |
Axel Drews | VP Global Marketing/sales | Leadership |
Kevin Held | Director Quality Management, Qualified Person | Leadership |
Julia Sommer-Bouqioud | Deputy Head Quality Management | Leadership |
Ulrich Granzer | Chairman | Board & advisors |
Jürgen Baumann | Board Member | Board & advisors |
John Borer III | Board Member | Board & advisors |
Reinhard Eyring | Board Member | Board & advisors |
Kevin Weber | Board Member | Board & advisors |
Irene Heimann | Regulatory Operations Manager | Team |
Stephanie Loughlin | Territory Manager | Team |
Kim Bressler | Senior Territory Manager | Team |
Hayley Smith | PDT Sales Executive | Team |
Jill Zaback | Executive Territory Manager | Team |
Todd Bishop | Territory Sales Manager | Team |
Christina Welters | Marketing Manager | Team |
Audrey Bonnan | Clinical Trial Project Manager | Team |
3 more people are available in the full profile.
Complete people profiles for Biofrontera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Biofrontera
Biofrontera is a publicly listed company on the NASDAQ with ticker symbol BFRI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Oct 2021
- Listed onNASDAQ: BFRI
- Listed entityBiofrontera Inc.
- Exchange sectorHealth technology
Investments & Acquisitions by Biofrontera
Biofrontera has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cutanea Life Sciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for skin disorders like acne and psoriasis are developed. | cutanea.com | Wayne, United States | 2005 | Mar 2019 | •••• |
Complete acquisition details for Biofrontera
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biofrontera
5 dated milestones of Biofrontera across 28 years, from founding to its latest funding, stage changes and deals.
- Founded Biofrontera is founded.
- Funding First funding round of $5.1M.
- Acquisition Acquires Cutanea Life Sciences.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $11.0M.
Competitors of Biofrontera
Biofrontera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Dermavant, Sol-Gel Technologies, SkinMedica and Hugel, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| dermavant.com | 2016 | Phoenix, United States | $160M | – | Small molecule therapeutics for inflammatory skin diseases are developed. | |
| sol-gel.com | 1998 | United States | $9M | – | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. | |
| skinmedica.com | 1999 | Carlsbad, United States | $94.24M | – | Skin care products are developed and manufactured by SkinMedica. | |
| hugel.co.kr | 2001 | Chuncheon-si, South Korea | – | – | Therapeutics in aesthetics are developed, including botulinum toxin products. | |
| collplant.com | 2004 | Ness Ziona, Israel | $16.3M | – | Plant-derived collagen is developed for tissue repair and 3D bioprinting. | |
| sofregen.com | 2014 | Medford, United States | $17.8M | 8 | Silk-derived biomaterials are developed for soft tissue repair in surgery. | |
| dermatarx.com | 2014 | San Diego, United States | $15.67M | 8 | Therapeutics for dermatologic and ophthalmologic diseases are developed. | |
| histogen.com | 2007 | San Diego, United States | $51.4M | 22 | Regenerative medicine is developed using embryonic cell alternatives. |
Detailed competitors of Biofrontera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biofrontera
The website of Biofrontera (biofrontera.com) receives about 1K visits a month and ranks #7,492,583 among all websites worldwide, #7,038 in Biotechnology and Pharmaceuticals.
- Monthly visits1K
▼ 56.6% vs previous month
- Global rank#7,492,583
among all websites
- Category rank#7,038
Health · Biotechnology and Pharmaceuticals
- Bounce rate50%
- Pages per visit1.5
- Average visit1 min 47 sec
- DevicesDesktop 79% · Mobile 21%
Websites whose visitors overlap most with Biofrontera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| revance.com | 100% | 17.8K | #1,318,141 | View details | |
ir.catalystpharma.com | ir.catalystpharma.com | 99% | – | – | – |
| cardomedical.com | 61% | – | – | View details | |
karina-lergenmueller.de | karina-lergenmueller.de | 33% | – | – | – |
wirtschaft-tv.com | wirtschaft-tv.com | 32% | – | #4,225,467 | – |
Latest news on Biofrontera
Complete news archive for Biofrontera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Biofrontera
10 companies that operate in the same segment as Biofrontera (Dermatology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Developer of drugs for treating dermatology diseases | 1908 | Copenhagen, Denmark | USD 560.38 M | – | – | |
Skincare, beauty, and wellness services provided by VLCC across multiple countries. | 1989 | Delhi, Delhi, India | – | – | – | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Immunotherapeutic solutions for dermatological conditions are developed. | 2016 | Westlake Village, California, United States | USD 94.5 M | USD 376.07 M | 342 | |
Targeted small molecules are developed for oncology treatments. | 2010 | Singapore, Singapore | USD 100 M | – | – | |
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured. | 2014 | Pune, Maharashtra, India | USD 25.97 M | USD 18.15 M | 508 | |
Novel dermatologic therapies are developed for skin conditions. | 2012 | Malvern, Pennsylvania, United States | USD 82 M | USD 7.83 M | 64 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Biofrontera
Biofrontera was founded in 1997 and raised its 1st funding round 7 years after it was founded.
Biofrontera is headquartered in Leverkusen, Germany. It is registered at Leverkusen, North Rhine-westphalia, Germany.
Biofrontera has 93 employees.
Annual revenue of Biofrontera is $15.5M as on Dec 31, 2025.
Biofrontera was founded in 1997 in Leverkusen, Germany, and operates within the dermatology sector. Solutions are offered for the sale and distribution of drugs, medical devices, and medical cosmetics focused on the care and treatment of skin diseases. The lead product, Ameluz, is utilized as a prescription drug for treating squamous cell carcinoma in situ. Additional dermatological items, including creams, gels, and scalp tonics, have been developed for consumer use.
Biofrontera's top competitors include Revance Therapeutics, Dermavant and Collplant.
Biofrontera offers Photodynamic Therapy Products and Topical Antibiotics.
Yes, Biofrontera is publicly traded on NASDAQ under the ticker symbol BFRI.
Biofrontera has made 1 acquisition, including Cutanea Life Sciences.
Biofrontera has 2 investors. Key investors include NRW, and Rosalind Advisors.
Biofrontera operates through Biofrontera Inc..